Jiangsu Yahong Meditech Co., Ltd aka Asieris

Quick facts

Phase 3 pipeline

• APL-1202 in combination with Epirubicin
• Placebo in combination with Epirubicin · Oncology
  Placebo has no pharmacological mechanism; this is a control arm in a clinical trial comparing epirubicin efficacy.

Phase 2 pipeline

• APL-1202 treatment · Oncology
  APL-1202 treatment targets the PD-1/PD-L1 pathway to modulate the immune response.

Phase 1 pipeline

• APL-1401
• ASN-3186
• Tislelizumab alone

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Jiangsu Yahong Meditech Co., Ltd aka Asieris portfolio CI brief
• Jiangsu Yahong Meditech Co., Ltd aka Asieris pipeline updates RSS